Followers | 261 |
Posts | 19732 |
Boards Moderated | 0 |
Alias Born | 10/03/2004 |
Tuesday, July 03, 2018 9:29:33 PM
First, an outright buyout should fetch $5 to $10 billion. Depending on a lot of factors, B platform is currently between 3 and 5 billion based on current proof of safety and efficacy, market size and blue skies OM and UP. Prurisol would fetch 1 to 3 billion and K 1 to 2 billion as a safe and proven p53 modulator. There are plenty of examples for those valuations for phase 2-3 drugs and includes BTD and 505b2 pathways. It also includes greater than 30 PASI75, but also its value as an anti-puritus should it be less than 30 PASI75.
Second, it’s unclear what deals Leo is pursuing. We can only guess. If it is a license/partner then precedent shifts downward. If Prurisol is successful in phase 2b, then I’m pretty sure that will be the first agreement. A 505b2 pathway drug would get $30 million to $75 million upfront with a few $100 million in milestone payments how many millions depending on the backend royalty structure. The money would then be used for further development of B and K. OM would be the minimal go to if P shows a low PASI score. That should get $45 million to over $100 million upfront, again depending on the backend terms.
Third, the previous paragraph takes the IPIX cap to $1 to $2 billion, $4 to $8, on a spike and then pullback to roughly half that. As trials ramp back up, and key milestones are hit (including first market approval), the SP over time might approach $40 to $50 a share and even later after continued success, new partners and approvals finally reach multiple 10s of billions. But, that’s far in the future.
Bottom line, $15 to $40 a share for the whole kit and kaboodle will change the finances and retirement for a lot of people, as would even $5.
* Never borrow to invest.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
PickleJar Debuts Nationwide Contest With Brian Kelley for Fans to Win a Three-Day Bahama Cruise • NREG • Jun 3, 2024 8:45 AM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM